Short-term incidence and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy receiving cardiac myosin inhibitors: A systematic review and meta-analysis
- 29 August 2025
- journal article
- review article
- Published by Elsevier in International Journal of Cardiology
- Vol. 442, 133846
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Real-World Assessment of Mavacamten's Impact on Left Ventricular Systolic and Diastolic Functions in Obstructive Hypertrophic Cardiomyopathy: A 1-Year Single-Center Observational StudyThe American Journal of Cardiology, 2025
- The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled TrialsThe American Journal of Cardiology, 2025
- Atrial Fibrillation in Hypertrophic CardiomyopathyJACC: Advances, 2024
- Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with MavacamtenHeart Rhythm, 2024
- Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyJAMA Cardiology, 2023
- Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3Journal of Cardiac Failure, 2023
- Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic CardiomyopathyThe American Journal of Cardiology, 2022
- Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathyInternational Journal of Cardiology, 2020
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyJACC, 2020
- Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: A cardiac magnetic resonance imaging studyEuropean Journal of Radiology, 2010